转化药物基因组学:种族意识药物的发现、证据整合与实施
该综述聚焦药物反应变异问题,指出40-70%患者存在疗效不足或不良反应,其中约15-30%变异可由遗传变异解释。文章总结了种族/ ancestry特异性药物遗传变异的发现进展、可行动性证据框架,并强调队列研究在桥接转化鸿沟中的关键作用。
要点
- 药物反应变异中约15-30%由遗传变异解释,支持药物基因组学优化治疗。
- 需关注种族/ancestry特异性药物遗传变异及可行动性证据框架。
- 队列研究和非正式合作对桥接药物基因组学转化鸿沟至关重要。
核心结论
- 药物基因组学已成为优化治疗的有价值工具,并将在临床护理中发挥更大作用。
研究设计与样本
- 综述总结了药物反应遗传基础的发现进展、证据框架及队列研究的作用。
主要发现
- 40-70%患者对药物治疗缺乏疗效或出现不良反应。
- 约15-30%的药物反应变异由遗传变异解释。
临床怎么用
- 在临床治疗优化中可考虑药物基因组学工具,关注种族/ancestry特异性变异证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Response to medications, the principal treatment modality for acute and chronic diseases, is highly variable, with 40-70% of patients exhibiting lack of efficacy or adverse drug reactions. With ~ 15-30% of this variability explained by genetic variants, pharmacogenomics has become a valuable tool in our armamentarium for optimizing treatments and is poised to play an increasing role in clinical care. This review presents the progress made toward elucidating genetic underpinnings of drug response including discovery of race/ancestry-specific pharmacogenetic variants and discusses the current evidence and evidence framework for actionability. The review is framed in the context of changing demographics and evolving views related to race and ancestry. Finally, it highlights the vital role played by cohort studies in elucidating genetic differences in drug response across race and ancestry and the informal collaborations that have enabled the field to bridge the "bench to bedside" translational gap.
引用
- Davis BH, Limdi NA. Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-Conscious Medicine. Clin Pharmacol Ther. 2021. PMID: 34233023. doi:10.1002/cpt.2357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。